Literature DB >> 3922868

The effect of the combination of nitroglycerin and propranolol on splanchnic and systemic hemodynamics in a portal hypertensive rat model.

R J Kroeger, R J Groszmann.   

Abstract

Present investigations support major contributions from increases in both portal blood flow and portal vascular resistance in the mechanism that maintains portal hypertension. beta-Adrenergic blockers have been shown to reduce the elevated portal blood flow component. The possibility that nitroglycerin administration could reduce the elevated portal vascular resistance component is investigated here. Portal hypertension was induced in rats by a calibrated constriction of the portal vein. Portal hypertensive rats receiving placebo exhibited significant (p less than 0.05) elevations over normal rats receiving placebo in cardiac index, portal venous inflow and portal pressure. Portal hypertensive rats were then divided into groups receiving nitroglycerin infusion, propranolol (beta-adrenergic blockade) and combined administration of nitroglycerin and propranolol. Significant reductions (p less than 0.05) in portal blood flow of 30, 32 and 44%, respectively, were accompanied by significant portal pressure reductions of 2.7 +/- 0.2, 1.7 +/- 0.3 and 3.6 +/- 0.4 mm Hg in all groups, respectively (p less than 0.05). Nitroglycerin failed to prevent a 46% rise in portal-collateral resistance accompanying the portal blood flow reduction, similar to resistance rises also found in propranolol-treated (33%) and combination nitroglycerin-propranolol-treated (49%) groups. We conclude that nitroglycerin infusion can significantly reduce portal pressure, alone or in combination with beta-blockade, by reducing portal venous inflow. It appears that nitroglycerin reduces portal blood flow through the effect of baroreceptor sympathetic reflexes that constrict the splanchnic bed in response to vasodilatation and venous pooling.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3922868     DOI: 10.1002/hep.1840050314

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  8 in total

1.  Effects of calcium antagonists on hepatic and systemic hemodynamics in awake portal hypertensive rats.

Authors:  M Nagasawa; T Kawasaki; T Yoshimi
Journal:  J Gastroenterol       Date:  1996-06       Impact factor: 7.527

2.  The calcium-channel blocker, verapamil, does not improve portal pressure in patients with alcoholic cirrhosis.

Authors:  C Merkel; A Gatta; M Bolognesi; R Padrini; G F Finucci; P Angeli; A Ruol
Journal:  Br J Clin Pharmacol       Date:  1988-09       Impact factor: 4.335

3.  Hypersensitivity of mesenteric veins to 5-hydroxytryptamine- and ketanserin-induced reduction of portal pressure in portal hypertensive rats.

Authors:  S A Cummings; R J Groszmann; A J Kaumann
Journal:  Br J Pharmacol       Date:  1986-11       Impact factor: 8.739

4.  Treatment for hepatitis C virus-induced portal hypertension in leukemic children.

Authors:  Rasha El-Ashry; Hala Abdel Malek; Essam A Desoky Ghayaty; Ahmed A El-Gendy; Ahmad Darwish; Youssef Al-Tonbary
Journal:  Med Oncol       Date:  2013-04-04       Impact factor: 3.064

5.  Influence of nitroglycerin on portal pressure and gastric mucosal hemodynamics in patients with cirrhosis.

Authors:  H Noguchi; A Toyonaga; K Tanikawa
Journal:  J Gastroenterol       Date:  1994-04       Impact factor: 7.527

6.  Hemodynamic effects of combined treatment with somatostatin analogue (SMS 201-995) and low-dose isosorbide dinitrate on portal hypertension in conscious cirrhotic rats.

Authors:  N Hori; T Okanoue; Y Sawa; Y Itoh; T Mori; S Takami; K Kashima
Journal:  J Gastroenterol       Date:  1994-08       Impact factor: 7.527

7.  Haemodynamic response to intravenous vasopressin and nitroglycerin in portal hypertension.

Authors:  D Westaby; A Gimson; P C Hayes; R Williams
Journal:  Gut       Date:  1988-03       Impact factor: 23.059

Review 8.  Beta-blockers in liver cirrhosis.

Authors:  Valerio Giannelli; Barbara Lattanzi; Ulrich Thalheimer; Manuela Merli
Journal:  Ann Gastroenterol       Date:  2014
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.